Boryeong 'Trudapa' Achieves No.1 Market Prescription for Dapagliflozin Generic

Boryung's diabetes treatment drug family ‘Trudapa’ (active ingredient dapagliflozin) has been revealed to have ranked first in the outpatient prescription amount in the generic market for the corresponding ingredient.

Boryung's diabetes treatments 'Trudapa' and 'Trudapam'
[Photo by Boryung]

According to pharmaceutical market research firm Ubist, Boryung announced on the 24th that the outpatient prescription performance of the Trudapa product family last year was 4.2 billion KRW, leading prescriptions with a market share of 14% in the generic market for dapagliflozin single agents and dapagliflozin·metformin combination agents.

Dapagliflozin, a sodium-glucose cotransporter (SGLT)-2 class diabetes treatment, is originally developed by AstraZeneca (AZ) under the brand name 'Forxiga.' With the patent expiration of Forxiga in April, a large number of generics were launched. As of last year, the total market size for single and combination agents was 132.2 billion KRW, with the generic market estimated at 29.5 billion KRW.

Boryung also launched the single agent Trudapa and the metformin combination agent 'Trudapam' immediately following the patent expiration in April last year. Both drugs are used to improve blood sugar control in adult patients with type 2 diabetes. Among the product family, the single agent showed outstanding performance. Trudapa has held the number one position in the generic market for nine consecutive months, increasing its market share. Boryung plans to further increase the market share of the Trudapa product family while building a diverse product portfolio to strengthen its market dominance in the diabetes field.

In addition, Boryung has been continuously launching various diabetes treatments. In September last year, it launched the generic single and combination agents of MSD (Merck, USA)'s dipeptidyl peptidase (DPP)-4 inhibitor 'Januvia (sitagliptin)' under the product family name 'Trusita.' In November, it also introduced 'Trubuddy,' the world's first combination agent of dapagliflozin and pioglitazone, a thiazolidinedione (TZD) class ingredient.

This year, Boryung plans to continue expanding its diabetes treatment portfolio by launching generic single and combination agents of Boehringer Ingelheim's DPP-4 inhibitor class 'Trajenta (linagliptin).' It is also developing combination agents that can treat comorbidities such as hypertension.

Sung Baek-min, Head of Prescription (Rx) Marketing at Boryung, said, “So far, Boryung has focused on launching essential products and establishing clinical evidence for the treatment of diabetes, a representative chronic disease. Going forward, we will continue to introduce various combinations of diabetes combination agents and strengthen academic sales and marketing activities to play a central role in diabetes treatment.”